Shares outstanding decreased 88.1%
Shares outstanding changed -88.1% from the comparable as-filed period. The change ranks at the 100th percentile of 7 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Shares outstanding changed -88.1% from the comparable as-filed period. The change ranks at the 100th percentile of 7 prior comparable changes.
Free-cash-flow proxy changed +27.8% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Gross margin changed +795 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash flow changed +31.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed +201 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
SBC / revenue changed +2537 basis points from the comparable as-filed period.
Stock-based compensation changed +337.9% from the comparable as-filed period.
Cash & equivalents changed -27.5% from the comparable as-filed period.
Working capital changed -19.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Free-cash-flow margin changed +600 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash-flow margin changed +507 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Inventory changed -37.0% from the comparable as-filed period.
Inventory / revenue changed -226 basis points from the comparable as-filed period.
Revenue changed +0.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Capex / revenue changed -93 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed +8.9% from the comparable as-filed period.
Working capital / assets changed -456 basis points from the comparable as-filed period.
Capital expenditure changed -16.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Receivables / revenue changed +229 basis points from the comparable as-filed period.
Current liabilities changed +2.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Cost of revenue changed -8.4% from the comparable as-filed period.
Research & development changed +4.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
R&D / revenue changed +17 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current assets changed -5.1% from the comparable as-filed period.
Trade receivables changed +6.1% from the comparable as-filed period.
Current ratio changed -7.8% from the comparable as-filed period.
Total assets changed -0.4% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.